<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017442</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-2789</org_study_id>
    <nct_id>NCT04017442</nct_id>
  </id_info>
  <brief_title>Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery</brief_title>
  <official_title>Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: A Prospective Double Blind Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting for normal spontaneous vaginal delivery who have a neuraxial anesthestic
      will be randomized to receive preservative free morphine or saline placebo after delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining consent, women presenting to the labor floor at Mount Sinai Hospital will be
      randomized into two groups, intervention and placebo. Baseline demographic data and surveys
      in regards to postpartum depression, anxiety, breastfeed willingness and pain scores will be
      obtained. After delivery of the baby patients will either receive 2mg preservative free
      morphine or saline via the epidural catheter prior to its removal. The study team will then
      record pain and recovery scores, as well as follow up screens to the aforementioned
      endpoints. The study will end at the 6 week postpartum visit with the patient's obstetrician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, prospective, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The only individual that will know to which group the patient was assigned is the individual on the study team who is drawing up the medication. This individual will have no other role in the assessment or evaluation of the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Quantity of opioid used in 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Pain Score: Likert full scale 1-10, with higher score indicating more pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetric Quality of Recovery Score (OBSQ10)</measure>
    <time_frame>24 hours</time_frame>
    <description>OBSQ10 total score 0-100, with higher score indicating better health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale (EPDS)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item instrument to assess postpartum depression, with total score from 0-30. Higher score indicates more depressed symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with breast feeding success</measure>
    <time_frame>1 week</time_frame>
    <description>Participants will respond yes/no as to their breast feeding success and continuation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Postpartum Pain</condition>
  <condition>Postpartum Depression</condition>
  <condition>Opioid Consumption</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg preservative free morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mL preservative free saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative Free Morphine</intervention_name>
    <description>After delivery of the baby patients will receive via the epidural catheter prior to its removal.</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>After delivery of the baby patients will receive via the epidural catheter prior to its removal.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women in labor

        Exclusion Criteria:

          -  Not a candidate for neuraxial anesthesia

          -  Patient refusal

          -  Allergy to morphine

          -  Patients with chronic pain syndromes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Katz, MD</last_name>
    <phone>212-241-0222</phone>
    <email>daniel.katz@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Katz, MD</last_name>
      <phone>212-241-0222</phone>
      <email>daniel.katz@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Eric Zhou, MD</last_name>
      <phone>212-241-7475</phone>
      <email>eric.zhou@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Daniel Katz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Postpartum depression</keyword>
  <keyword>Postpartum anxiety</keyword>
  <keyword>Postpartum opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

